Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

AstraZeneca signs a significant AI deal to enhance immunology, while UK Chancellor Rachel Reeves focuses on promoting company ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The model is built on CRISPR technology, a powerful gene editing tool used to edit genomes and develop therapies for genetic diseases. However, training to use this tool for designing experiments can ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG ...

The CRISPR gene editing technology has transformed the research lab, and this powerful tool is now making its way into the clinic. So far, three different human diseases have been successfully treated ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.